News

OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

Poster Presentations to highlight the ongoing clinical studies targeting Globo …

Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor …

OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 …

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

OBI is eligible to receive up to US$ 200 million …

OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

OBI Pharma Inc. (TPEx: 4174) announced today research results in …

OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION …

OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase 2 Study

OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced …

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

First clinical trial to evaluate the safety and efficacy of …

Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4

Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 …

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 …